Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Don’t Count Those Pennies Just Yet: Watson Cited For Claiming Cost Savings From Sodium Ferric Gluconate

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Office of Prescription Drug Promotion objected to economic claims that the product could reduce ESA use in part because they were based on a subset of the approved population.


Related Content

Rapaflo Symptom Relief ≠ Clinical Evidence, FDA Says
Present Serious, Not Common, Risks First, FDA Tells Watson In Letter On Gelnique
AstraZeneca Diprivan Anti-Generic Promos Require Corrective Letter - FDA


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts